Receptor discordance and phenotype change in metastatic breast cancer
Open Access
- 1 January 2021
- journal article
- research article
- Published by Elsevier in Asian Journal of Surgery
- Vol. 44 (1) , 192-198
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Discordant hormone receptor and human epidermal growth factor receptor 2 status in bone metastases compared to primary breast cancerActa Oncologica, 2013
- A retrospective study investigating the rate of HER2 discordance between primary breast carcinoma and locoregional or metastatic diseaseBMC Cancer, 2012
- Comprehensive molecular portraits of human breast tumoursNature, 2012
- Loss of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Metastatic Sites of HER2-Overexpressing Primary Breast TumorsJournal of Clinical Oncology, 2012
- Comparison of hormonal receptor and HER-2 status between breast primary tumours and relapsing tumours: clinical implications of progesterone receptor lossVirchows Archiv, 2011
- Should liver metastases of breast cancer be biopsied to improve treatment choice?Annals of Oncology, 2011
- Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS)Breast Cancer Research, 2010
- Receptor conversion in distant breast cancer metastasesBreast Cancer Research, 2010
- Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancerAnnals of Oncology, 2009
- HER-2/neu expression in primary and metastatic breast cancerBreast Cancer Research and Treatment, 2008